Table 3. First TEE.
| GCT: study group (n=100) | GCT: validation group (n=77) | Non-GCT neoplasms: control group (n=100) | |
|---|---|---|---|
| Patients with a first TEE | 19 | 10 | 6 |
| Timing of the first TEE | |||
| During chemotherapy | 14 | 7 | 4 |
| After the end of chemotherapy | 5 | 3 | 2 |
| Deep venous thrombosis | 16 | 9 | 6 |
| Leg | 6 | 3 | |
| Arm | 4 | 1 | |
| Inferior vena cava | 4 | 1 | 5 |
| Superior vena cava | 1 | 1 | |
| Pulmonary embolism | 1 | 2 | |
| Renal vein | 1 | 1 | |
| Superficial venous thrombosis | 2a | 1a | 0 |
| Arterial thrombosis | 1 | 0 | 0 |
| Stroke | 1 |
a
All these patients subsequently developed a deep venous thrombosis.
GCT=germ-cell tumours; TEE=thrombo-embolic events; PT=prothrombine time; .APTT=activated partial thromboplastin time.